Background: An emerging paradigm holds that resistance to the development of allergic diseases, including allergic rhinoconjunctivitis, relates to an intact epithelial/epidermal barrier during early childhood. Conceivably, the immunologic and genomic footprint of this resistance is preserved in nonatopic, nonallergic adults and is unmasked during exposure to an aeroallergen. Objective: The aim of this study was to obtain direct support of the epithelial/epidermal barrier model for allergic rhinoconjunctivitis. Methods: Twenty-three adults allergic to house dust mites (HDMs) (M1) and 15 nonsensitive, nonallergic (M2) participants completed 3-hour exposures to aerosolized HDM (Dermatophagoides pteronyssinus) powder on 4 consecutive days in an allergen challenge chamber. We analyzed: (1) peripheral blood leukocyte levels and immune responses; and (2) RNA sequencing-derived expression profiles of nasal cells, before and after HDM exposure.
Substantial evidence indicates that defects in the skin barrier and cutaneous allergen sensitization are early, crucial events in the pathogenesis of atopic dermatitis. In addition, data from genetic and other studies implicate defects in the skin barrier in the development of diseases that manifest in other organs, including food allergy, asthma, allergic rhinoconjunctivitis (AR), and eosinophilic esophagitis. [1] [2] [3] [4] [5] For example, the filament-aggregating protein (filaggrin) has an important role in skin barrier function, and polymorphisms in the filaggrin gene (FLG) have been associated with atopic dermatitis and other allergic diseases. 2, 4, [6] [7] [8] [9] [10] [11] [12] Additional studies in humans and mice support skin-barrier impairment as a crucial requirement for allergen sensitization. 4, [12] [13] [14] [15] [16] [17] [18] In this emerging paradigm, resistance to the development of allergic diseases requires the generation of a balanced response to allergen challenge during early childhood that is dominated by a higher expression of genes that promote epidermal/epithelial integrity coupled with a blunted inflammatory response. We tested the hypothesis that the imprint of this balanced response is preserved in adults who remain nonatopic and free of allergic diseases. This hypothesis predicts that the major immunologic and transcriptomic features of this imprint are not evident at baseline (constitutively), but are unmasked during allergen exposure, and thus are an adaptive (ie, healthy) response to allergen challenges. Exposure to precise quantities of aeroallergens in allergen challenge chambers (ACCs) is an incisive experimental system used for studying genomic and immunologic responses following allergen exposures. [19] [20] [21] [22] [23] To test our hypothesis, we performed exposure studies with aerosolized house dust mites (HDMs) in an ACC using persons who were nonallergic (nonsensitized, nonatopic) versus allergic to HDMs. We examined: (1) leukocyte and immune responses in the peripheral blood; and (2) transcriptomic responses derived by RNA sequencing (RNA-seq) in cells obtained by nasal brushings before and after exposure to HDMs.
METHODS

Study participants
We recruited 25 participants with HDM allergy and a positive result on SPT wheal reactivity to Dermatophagoides pteronyssinus (designated as M1) and 15 individuals with no history of perennial or seasonal allergies and a negative result on SPT wheal reactivity to HDMs (designated as M2) who met the inclusion/ exclusion requirements (see Table E1 in this article's Online Repository at www.jacionline.org). All M2 participants also had negative results on wheal-reactivity SPTs of an additional 16 allergens tested (see Table E2 in this article's Online Repository at www.jacionline.org). The IntegReview Institutional Review Board (Austin, Tex) approved the study protocol, and all eligible patients provided written informed consent for participation.
HDM exposure and scoring of AR symptoms
Delivery of HDMs, as well as collection and quantification of HDMs in the ACC, have been described previously 19 and are summarized in the Methods section in this article's Online Repository at www.jacionline.org. Participants underwent 3-hour exposure to aerosolized HDM (D pteronyssinus) powder on 4 consecutive days (exposures/challenges 1-4; Fig 1, A) , commencing daily at 6 PM, and during months when environmental confounders (seasonal allergens) in the atmosphere were low (see the Methods section in this article's Online Repository). The mean concentration of HDMs (Der p 1 levels assessed by ELISA) delivered was 92 ng/m 3 (see Table E3 in this article's Online Repository at www.jacionline.org). Total symptom scores (TSSs; range, 0-28) reflect the sum of 4 nasal and 3 ocular symptoms, each recorded on a Likert-type scale of 0 (no symptoms) to 4 (severe symptoms) (see Table E4 in this article's Online Repository at www.jacionline.org). Participants were prohibited from taking specific allergy medications during the study period (see the Methods section and Table E5 in this article's Online Repository).
Complete blood count, flow cytometry, and time-of-flight mass cytometry analyses Levels of peripheral blood leukocytes were measured via a complete blood cell count, and activated CD4
1 and CD8 24 were measured by flow cytometry (see the Methods section in this article's Online Repository). These measures were available before and after exposures 1 and 4 (Fig 1, A) . We also used time-of-flight mass cytometry (CyTOF) to perform immunophenotyping of PBMCs from 3 M1 participants with a high TSS following HDM challenge (mean TSS, 21.7) and 2 M2 participants (mean TSS, 0). Responses were determined in samples obtained before and after the first HDM challenge. A standard CyTOF experimental workflow, as outlined by Bendall et al, 25 was employed (see the Methods section in this article's Online Repository). Antibody panels and immunophenotypes are summarized in Table E6 in this article's Online Repository at www.jacionline.org.
Transcriptomic analyses
Whole-genome transcriptomic analyses (derived by RNA-seq) were performed on cells obtained by nasal brushings. We sampled the region well above the vestibule (inferior nasal concha). RNA-seq data from 13 M1 and 11 M2 participants were available at 3 time points (pre-exposure 1 [baseline] and post-exposures 1 and 4). Methods for nasal cell collection, RNA isolation and quality control, library preparation, and RNA-seq on an Illumina HiSeq 2000 platform (Illumina, San Diego, Calif) have been described previously 23 and are presented in the Methods section in this article's Online Repository.
Study design and statistical and bioinformatic analyses
Features related to the study design, including validation and replication populations, as well as mitigation of confounding factors, including the heterogeneity in cell populations studied, are discussed in the Notes in this article's Online Repository. All leukocyte cell counts were log 2 -transformed. Unpaired or paired t-tests were used, and significance was ascribed at P < .05. Bioinformatic methods for the RNA-seq data are described in the Methods section in this article's Online Repository. Ascribing a gene as differentially expressed indicates a false discovery rate of <0.05. Table E7 in this article's Online Repository at www. jacionline.org describes the statistical methods for each figure. Each longitudinal change in gene expression among M1 or M2 participants on HDM challenge was classified as earlier, later, or overall. Each change in gene expression that occurred between pre-exposure 1 and post-exposure 1 was designated as earlier response; between post-exposure 1 and post-exposure 4, as later response; and between pre-exposure 1 and post-exposure 4, as overall response. Cross-sectional comparisons of data between M1 and M2 participants were also made at each of 3 time points. Details on bioinformatic methods 26, 27 and functional modules 28 for the RNA-seq data are described in the Methods section in this article's Online Repository. Differentially expressed genes (false discovery rate, <0.05) were used for further down-stream functional analysis using DAVID v6. 7, 26, 27 Ingenuity Pathway Analysis (IPA, 2013 winter release [www.qiagen. com/ingenuity]; Qiagen, Redwood City, Calif), and modular analysis 28 as described in the Methods section in this article's Online Repository. A list of 203 genes identified by genome-wide association studies (GWAS) that have been associated with allergic diseases or traits was compiled (see Table E8 in this article's Online Repository at www.jacionline.org).
RESULTS
Discordant clinical responses in M1 versus M2 participants
Overall, 23 M1 and 15 M2 participants completed the study. 19 The M1 and M2 participants did not differ significantly in age, sex, or ethnicity (see Table E9 in this article's Online Repository at www.jacionline.org). Despite 4 consecutive exposures to HDMs, M2 participants did not develop symptoms; in M1 participants, the mean TSS was significantly higher than baseline levels on each challenge day (Fig 1, B) . The reasons for the elevated TSS at pre-exposure 1 in M1 persons and progressive lowering of the TSS at pre-exposures 2, 3, and 4 have been discussed previously.
Concordant leukocyte/lymphocyte responses in M1 versus M2 participants
The levels of peripheral blood lymphocyte/leukocyte populations studied were not significantly different in the cross-sectional comparisons between M2 and M1 persons at pre-and post-exposures 1 and 4 (Fig 1, C-I 
CD8
1 T cells increased, achieving statistical significance in most cases; neutrophils did not increase (Fig 1, C-I ; results not shown). CyTOF data supported these inferences (see the Results section in this article's Online Repository).
Discordant peripheral blood T-cell activation responses in M1 versus M2 participants
While the above-mentioned data pointed to a large degree of concordance in leukocyte/immune responses between M1 and M2 persons, a prominent discordant pattern was observed. During exposure 1 there was a nonsignificant trend toward increased levels of activated T cells in M1 participants, whereas in M2 participants, there was a decline (Fig 1, J and K) . Consequently, at post-exposure 1, the levels of activated CD4 1 and CD8
1 T cells were significantly lower in M2 compared with M1 participants (Fig 1, J and K) . During exposure 4, levels of activated CD4
1 and CD8 1 T cells in both M1 and M2 individuals were nearly similar to those at pre-exposure 1 (baseline) levels (Fig 1, J and K).
Overview of transcriptional changes in M1 and M2 participants
We next examined genomic (transcriptomic) responses in cells acquired by nasal brushings. A total of 15,763 genes met quality-control criteria for downstream analyses. Fig 2, A, depicts the number of differentially expressed genes in cross-sectional analyses at 3 time points and 3 longitudinal analyses designated as earlier, later, and overall responses. File E2 in this article's Online Repository provides a list of the genes in each comparison.
Longitudinal changes in M1 and M2 participants
Only 1 gene showed significant differential expression earlier in M1 participants (Fig 2, A and B ). This gene (NR4A1) has been implicated in eosinophil biology. 29 Totals of 411 and 999 genes were differentially expressed later in M1 and M2 participants, respectively (Fig 2, A) , and between these 2 gene sets, 1041 were unique (Fig 2, B) . Of the 1041 unique genes, more genes were differentially expressed in M2 compared with M1 participants (630 vs 42), and 369 genes were differentially expressed in both groups (Fig 2, B) . In contrast, of the 1815 and 1651 genes that were differentially expressed overall in M1 and M2 participants, respectively, 2235 were unique (Fig 2, A and B). Of these, 1231 were differentially expressed in both groups, and 584 and 420 genes were differentially expressed only in M1 or M2 participants, respectively (Fig 2, B) .
The direction of change in expression (upregulation or downregulation) in the 1041 and 2235 unique genes that were differentially expressed later and overall, respectively, showed nearly 100% concordance in M1 and M2 participants (Fig 2, C) . The high degree of consistency in responses later and overall (Fig 2, C) suggests that transcriptional responses in nasal cells that may partly underlie the contrasting clinical phenotypes of M1 and M2 participants must have occurred earlier. To examine this possibility and to provide uniformity to the earlier, later, and overall comparisons, we determined the degree of changes in gene expression (log 2 fold-changes) that occurred earlier, later, and overall in a uniform set of 2254 genes in M1 and M2 participants. These genes were significantly differentially expressed in at least 1 of the 3 longitudinal analyses (Fig 2, A) . Three lines of evidence supported that: (1) most transcriptomic responses differentiating M1 and M2 participants occurred earlier; and (2) the overall genomic response in M1 participants was skewed toward upregulation, whereas it was skewed toward downregulation in M2 participants.
First, the correlation between the log 2 fold-changes in the 2254 genes in M1 and M2 participants was lower in the earlier compared with later or overall responses (r 5 .55 vs .93 and .92, respectively; Fig 2, D-F, first and second rows) . This lower degree of earlier correlation was attributable to the 25% (n 5 558) of the 2254 genes that had discordant fold-changes (sum of genes in quadrants II and IV, Fig 2, D, first row) . Of these genes, most (n 5 498 [89%]) were upregulated in M1 participants but were downregulated in M2 participants (quadrant II). The remainder (n 5 60 [11%]) exhibited the reverse pattern (quadrant IV ; Fig 2, D, first row) . Thus, the discordance was biased toward more genes manifesting increased expression in M1 participants but decreased expression in M2 participants.
Second, among genes that were concordantly upregulated or downregulated earlier, a greater proportion of genes had larger changes in M1 compared with M2 participants (Fig 2, D , third and fourth rows). Among genes that were concordantly upregulated or downregulated later, a greater proportion of genes had larger changes in M2 compared with M1 participants (Fig 2, E, third and fourth rows). Overall, more upregulated genes had larger changes in M1 compared with M2 participants (Fig 2, F, third row) . More downregulated genes had larger changes in M2 compared with M1 participants (Fig 2, F, fourth  row) .
Third, specific clusters of genes manifested contrasting temporal patterns earlier versus later in M1 and M2 participants (Fig 3) . The 2254 genes were categorized into 4 temporal patterns (Fig 3, A) . Patterns 1 and 4 comprised genes that showed increases and decreases over time, respectively, in expression levels. Pattern 2 genes showed an initial increase followed by a decrease or no change in expression levels, and pattern 3 genes had an initial decrease followed by an increase or no change in expression levels (Fig 3, A) . Fig 3, B , depicts the clusters of the 4 temporal patterns among the 2254 genes in M1 and M2 participants; these clusters were designated by 2 digits, with the first indicating the pattern in M1 persons (eg, cluster 1-3 indicates gene expression pattern 1 in M1 but pattern 3 in M2 participants). In M1 participants, 1047 genes clustered in pattern 1, but in M2 participants, 55% (n 5 578), 0.8% (n 5 8), 44% (n 5 459), and 0.2% (n 5 2) of these genes clustered in patterns 1, 2, 3, and 4, respectively. The top significant GO terms that were associated with the 578 pattern 1 genes in both M1 and M2 individuals were related mainly to epithelial and epidermal cell development and differentiation (cluster 1-1; Fig 3, (Fig 3, B) . Thus, differential expression of a broad array of inflammatory genes earlier appeared to distinguish M1 from M2 participants.
Of the 45 genes that clustered in pattern 2 in M1 participants, 80% (n 5 36) of these were in pattern 4 in M2 participants; these genes were related to antigen presentation and processing as well as asthma and autoimmune processes (cluster 2-4; Fig 3, 4; Fig 3, B) , suggesting that the greatest similarity in temporal patterns between the groups occurred in genes with a progressive decrease in expression. These genes were classified to pathways that maintain cellular integrity (eg, microtubule cytoskeletal and cytoskeletal; Fig 3, Thus, in a uniform set of 2254 genes that were differentially expressed in cells collected by nasal brushings, 74% (n 5 1671 genes) showed a concordant expression pattern in M1 and M2 participants. The pathways showing differences in temporal patterns between M1 and M2 participants were related primarily to inflammation/immune responses (cluster 1-3), followed by antigen presentation and atopy/autoimmune diseases (cluster 2-4), enzymatic/protease activity (cluster 3-1), and cell membrane function (cluster 4-2) (Fig 3, C) . The trajectories of representative genes within these clusters, including those identified by GWAS, are depicted (Fig 3, D) to illustrate the: (1) concordance in both pattern and amplitude (eg, S100A7, CAPSL, TMEM232); (2) concordance in pattern but wide (eg, SLC26A4) or modest (OVOL1, TNFRSF6B) discordance in amplitude; and (3) discordance (bottom row) in the pattern of genomic responses in M1 and M2 persons. Several genes involved in epidermal/epithelial integrity, while showing an overall similar direction of change (upregulation or downregulation), demonstrated a contrasting pattern and/or amplitude in the genomic response (eg, CCDC80 in cluster 4-2 in Fig 3, D, and FLG in cluster 1-1, the level of which was increased prominently in M2 but not M1 persons [plots not shown]).
Cross-sectional transcriptomic differences between M1 and M2 participants
Cross-sectional analysis revealed that the numbers of genes whose expression levels differed between M1 and M2 participants at baseline (pre-exposure 1), post-exposure 1, and post-exposure 4 were 28, 741, and 238, respectively (Fig 2, A, Table E10 and File E2 in this article's Online Repository). Overlap between the differentially expressed genes at these 3 time points is shown in Fig 4, A. Several pathways were different in M1 and M2 participants at specific time points (Fig 4, B) : pre-exposure 1 and post-exposure 4 (extracellular matrix-receptor interaction and focal adhesion); post-exposure 1 (leukocyte migration, Toll-like receptor, Janus kinase-STAT signaling, and B-cell receptor signaling, among others); post-exposures 1 and 4 (chemokine and cytokine responses, among others); and post-exposure 4 (pathways related to atopic and autoimmune diseases).
M1 and M2 individuals at baseline (see
Among the 3 cross-sectional comparisons, 731 (84%) genes had significantly higher expression levels in M1 compared with M2 participants (Fig 4, C) ; 140 (16%) genes had the opposite pattern in at least 1 of the 3 cross-sectional analyses (Fig 4, D) . The top GO terms associated with the genes more highly expressed in M1 compared with M2 participants were related mainly to inflammatory and immune responses (Fig 4, E) . Genes more highly expressed in M2 compared with M1 participants were related primarily to epithelial and epidermal cell development, integrity, and differentiation, including those involved in enzymatic activity, such as serine peptidase inhibitors (Fig 4, F) . The trajectory of these genes showed contrasting patterns in M1 and M2 participants (Fig 4, G and  H) . Congruent with the findings from the longitudinal analyses (Fig 3) , genes involved in inflammation/immunity levels were increased in M1 participants, whereas in M2 participants, the levels were first decreased and were increased thereafter (Fig 4, G) .
Genes associated with AR symptomatology
The above-mentioned approach elucidated pathways induced on HDM challenge in M2 and M1 persons (Figs 2 and 3) and differences between M2 versus M1 persons during 1st and 4th HDM challenge (Fig 4) . We next investigated whether specific genes in M1 persons were associated with AR severity on HDM challenge. To identify these genes, we applied 5 sets of criteria, noted in Table E11 in this article's Online Repository at www.jacionline.org, to the longitudinal and/or cross-sectional RNA-seq datasets. We also cross-referenced genes differentially expressed in our RNA-seq dataset and those identified by GWAS for allergic diseases/traits. The Methods section and Figs E2-E5 in this article's Online Repository at www. jacionline.org describe how these sets were derived. The 5 criteria yielded 65 genes with higher or lower expression in M1 compared with M2 participants in sets 1 to 5 and 47 GWAS-identified genes in set 6 (see Table E11 , Figs E2-E6, and the Discussion section in this article's Online Repository at www.jacionline.org). Together, there were 106 unique genes (see Tables E11 and E12 and File E3 in this article's Online Repository at www.jacionline.org). Expression levels of 12 of these genes, shown in Table E11 
Modular analysis
We performed RNA-seq analyses on unfractionated (unsorted) cells obtained by nasal swabs. Differences in cellular composition at baseline between M2 versus M1 participants could have confounded analyses. To investigate this possibility, we used a modular analysis framework 28 to interpret the transcriptional response (see Fig E9 in Cross-sectional analyses revealed that interferon/antiviral, inflammation, T cell, neutrophil, monocyte, and cell death modules were upregulated in M1 compared with M2 participants at the conclusion of exposure 1 (see Fig E9 in this  article' s Online Repository). In contrast, differences in these modules were modest at the conclusion of exposure 4.
DISCUSSION
Consistent with our hypothesis, we found that, at baseline (pre-exposure), the immunologic and transcriptional differences between M2 and M1 persons were minimal. However, on HDM challenge, M2 participants mounted leukocyte changes in the peripheral blood that were largely concordant with those in M1 participants. These changes included expansion of CD14
11
CD16
1 intermediate monocytes, a leukocyte subset that is expanded in several inflammatory diseases, including asthma. 24, 30 Mirroring this congruency, <10% of the 141 immunophenotypes (determined by CyTOF) differed between M1 and M2 participants at baseline (pre-exposure) and during the initial HDM challenge. Consistent with these results, there was substantial concordance in global transcriptional responses (assayed by RNA-seq) in M2 and M1 participants on HDM challenge. For example, of the uniform set of 2254 genes that we examined, only 26% showed a discordant trajectory pattern between M2 and M1 participants (Fig 3, B) .
Amidst this substantially concordant response to HDM challenge, we identified a key immunologic feature in the peripheral blood and 2 genomic features in the nasal compartment that differentiated M2 from M1 participants. First, during the initial HDM challenge, CD4
1 and CD8 1 T-cell activation levels in the peripheral blood were decreased in M2 participants, whereas they were increased in M1 persons; on subsequent HDM challenge, T-cell activation levels increased in both study groups. Second, there was evidence of differential genomic titration. That is, among genes that were upregulated, the proportion of genes with higher absolute fold-changes was greater in M1 versus M2 persons and, conversely, among genes that were downregulated, the proportion of genes with higher absolute fold-changes was greater in M2 versus M1 individuals. Third, there was evidence of differential genomic reprioritization. That is, genes that promote epithelial/epidermal barrier function (eg, FLG) were preferentially upregulated in M2 versus M1 participants, whereas those that promote inflammation were preferentially upregulated in M1 versus M2 participants. Levels of the epithelial/epidermal barrier genes tended to increase progressively in M2 persons, whereas they remained largely unchanged in M1 persons. In contrast, expression of genes involved in inflammation or immune responses showed a tendency to decline during the first HDM challenge in M2 persons versus an increase in M1 persons. Thereafter, on subsequent HDM challenge, levels of these proinflammatory genes declined, remained unchanged, or increased in M2 persons. In many instances, levels of inflammatory genes in M2 participants eventually approximated those found in M1 persons. The decline versus increase in levels of proinflammatory genes mirrored the decline versus increase in T-cell activation levels in the peripheral blood of M2 versus M1 persons on the initial HDM challenge.
The above-mentioned results derived by tracing changes in gene expression (Figs 2 and 3 ) and cross-sectional comparisons (Fig 4) were substantiated by the results from the modular analytical approach (see Fig E9 in this article' s Online Repository). The latter approach showed that the modules induced (upregulated) in M1 and M2 participants were similar (see Fig E9 in this article' s Online Repository), and at the conclusion of the study, minimal differences were observed between M1 and M2 participants (see Fig E9 in this article' s Online Repository). This approximation reinforces the idea that our results were not confounded by differences in cellular composition between M1 and M2 participants that might have been present at baseline. The modular analytical approach also substantiated that most changes following HDM exposure occurred early (see Fig E9 in this article' s Online Repository).
Based on the expression patterns of representative genes, shown in Table E11 in this article's Online Repository, and genes that colocalize, a mechanistic model is presented in Fig 5. We suggest that, on the initial HDM challenge, the distinctive patterns of genomic titration and reprioritization co-index, leading to a balanced or adaptive (healthy) versus an imbalanced or maladaptive (unhealthy) genomic response in M2 versus M1 persons (Fig 5, A) . Our results suggest a coordinated response in M2 and M1 participants at multiple chromosomal loci and colocalizing genes (Fig 5, B-E) . Most genes, including those identified by GWAS, showed similar expression values at baseline (pre-exposure), with differences between M1 and M2 persons becoming apparent on the initial HDM challenge. Additionally, in instances in which the overall direction of the change (upregulation versus downregulation) was concordant, there were differences in the amplitude of change between M1 and M2 persons (Fig 3, D, and Fig 5, B-E) .
Genomic features at the following loci provide insights into the key components of a balanced/adaptive versus imbalanced/ maladaptive response in M2 versus M1 persons. Several genes essential for maintaining the epidermal/epithelial barrier (eg, FLG) are colocalized on a region of chromosome 1q21 (genes constitute the epidermal differentiation complex) (Fig 5, B and  C) . [31] [32] [33] [34] [35] Following HDM challenge, expression levels of these colocalized genes in M2 but not M1 participants increased. Another example is reflected by SPINK5; this gene plays an essential role in regulating epidermal protease activity, and polymorphisms in this gene have been associated with atopic dermatitis and may be involved in Netherton syndrome, a feature of which is severe atopy. 36 Levels of SPINK5 were increased prominently after HDM challenge in M2 individuals, but not in M1 persons (Fig 5, C) . Conversely, levels of proinflammatory genes such as: (1) periostin (POSTN), which has been used as proxy for IL-13 activity and has been associated with allergic diseases 37 ; (2) GWAS-identified proinflammatory/immune genes such as IL6R, IL4R, IL33, SOCS3, and DUSP1; and (3) chemokines and their receptors (eg, CCL24 and CCR3) declined or manifested a muted increase in M2 persons (Fig 3,  D, and Fig 5, E) . A recent study highlighted the importance of A20, an attenuator of NF-kB-mediated inflammatory response, in mediating allergic disease. 38 In our studies, transcriptional levels of A20 (encoded by TNFAIP3) paralleled the overall inflammatory response in M2 and M1 persons (Fig 3, D) . Additional information, available in the Discussion section in this article's Online Repository, regarding representative genes that may play an influential role in this model, and whether the barrier defect leading to respiratory tract allergic disease (allergic rhinitis) is present only in the epithelial layer of the nasal mucosa or whether it is a much wider defect within the epidermal barrier.
There were 5 caveats to our study. First, we challenged participants with HDMs, and our results therefore are not generalizable to other aeroallergens. Second, we did not compare transcriptional responses in the nasal compartment with those in the blood; however, we believe that there are differences. Third, a larger sample size would have allowed us to stratify M1 persons based on other clinical characteristics, which could have revealed factors that contribute to the heterogeneity in symptom severity as well as transcriptional and immunologic responses following HDM challenge. Fourth, while we did not sort cells sampled by nasal brushings, the analysis of a heterogeneous cellular mixture may provide a better representation of the epithelial and immune responses generated after allergen challenge versus analysis of individual cell types. Indeed, cellular heterogeneity has advantages in transcriptome profiling, [39] [40] [41] [42] and in our studies ). Thus, it is possible that, in M1 versus M2 participants, an inflammatory T H 2 response to HDMs and/or lack of a regulatory T cell-mediated control of nasal inflammation in response to HDMs contributes to the divergent epithelial transcriptional response. However, it is also possible that, in M2 subjects, the transcriptional response toward preservation of the epidermal/ epithelial barrier may be sufficient for preventing the heightened inflammatory response observed in M1 subjects. This possibility raises the question of causality: does an initial barrier defect lead to development of T H 2-skewed inflammatory HDM responses, or do uncontrolled inflammatory HDM responses lead to defective barrier function? The findings from our study cannot answer this question definitively. However, the resilient transcriptional responses observed in nonallergic individuals raise the possibility that an initial defect in this barrier response may lead to inappropriate inflammation that feeds back over time to cause further barrier deficits, ultimately precipitating in development of HDM atopy. Similarly, genetic predisposition toward HDM atopy may lead to deterioration of epithelial barrier function over time. Hence, we envisage a complex, ongoing, bidirectional crosstalk between nonepithelial immune cells and epithelial cells that confers resistance versus susceptibility to HDM allergic diathesis.
Our findings have implications for biomarker discovery research, as significant attention is typically placed on identifying biomarkers that distinguish individuals with divergent allergy endotypes (eg, disease severity or therapeutic responses) via cross-sectional analyses at baseline (constitutively). However, our results point to the possibility that divergent allergy endotypes result from contrasting temporal responses to allergen exposure rather than from baseline characteristics. Our results underscore that, while identifying genes with the greatest fold-changes between persons with and those without allergic diseases has merit, this approach obscures the fact that the summated induced response across multiple loci that confer similar functional effects (eg, inflammation) is likely to confer overall phenotype, rather than the individual effects of fewer genes with the greatest differences in expression levels. Furthermore, the lack of a strong peripheral blood signature of AR in M1 subjects, despite the multiplexed capabilities of CyTOF, suggests that direct sampling of affected tissues and genome-wide methodologies (eg, RNA-seq) may be best suited to identifying clinically relevant signatures of allergy.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 In summary, our study design allowed us to identify features of a healthy, balanced adaptive response in M2 persons elicited following exposure to HDMs in an ACC. The key features of this response provide support for the emerging paradigm that a ''resilient'' epidermis/epithelium that retains and promotes barrier function, despite repeated aeroallergen challenge, may play a crucial role in preventing epicutaneous sensitization and downstream inflammatory responses and, consequently, allergic diseases.
Clinical implications: Therapeutic strategies that improve epidermal/epithelial barrier function and dampen inflammation, especially in the local (nasal) compartment, could help to mitigate symptoms related to AR.
